- Research article
- Open Access
Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
© Imazeki et al; licensee BioMed Central Ltd. 2011
- Received: 19 May 2011
- Accepted: 31 August 2011
- Published: 31 August 2011
Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2.
Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0.
HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074).
PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
- Sustained Virological Response
- Sustained Virological Response Rate
- High Viral Load
- Rapid Virological Response
- Average Treatment Duration
Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis, hepatic cirrhosis and hepatocellular carcinoma . The number of cases of end-stage liver diseases caused by chronic HCV infection and being referred for liver transplantation is increasing rapidly . The current standard care for chronic hepatitis C is based on the combination of pegylated-interferon (PEG-IFN) and ribavirin (RBV) for 48 weeks, and this treatment results in ~50% sustained virological response (SVR) in patients with HCV genotype 1 and high viral loads . Among HCV genotypes other than HCV genotype 1, HCV genotypes 2/3 patients in particular show 70-80% SVR by this treatment for 24 weeks [4–6].
Recent studies revealed that a shorter course of therapy, for 12 weeks, with PEG-IFN-alfa-2b and RBV is as effective as a 24-week course for patients with certain HCV genotype 2/3 who show a rapid virological response (RVR) to treatment at 4 weeks , although treatment with PEG-IFN and RBV for 12 or 16 weeks in patients infected with HCV genotype 2 or 3 results in a lower overall SVR rate than treatment with the standard 24-week regimen [5, 7].
On the other hand, PEG-IFN-alfa-2a without RBV induces SVR in some transplant recipients with recurrent hepatitis C  or in some dialysis patients infected with HCV . In patients with cirrhosis, IFN, either alone or in combination with ribavirin, has been used cautiously, largely because it may exacerbate existing neutropenia and thrombocytopenia . In general, PEG-IFN-alfa-2a monotherapy was better tolerated than the combination with RBV, although PEG-IFN-alfa-2a monotherapy was associated with a ~20% rate of SVR in patients infected with HCV genotype 1 .
Among pretreatment virological variables, the presence of HCV genotype 2 or 3 infection is the most powerful predictor of SVR , as patients with HCV genotype 2 are more likely to achieve SVR than those with genotype 1. Further, patients with lower titers of HCV RNA are also more likely to achieve SVR . In this study, we sought to determine whether PEG-IFN monotherapy for fewer than 24 weeks would be effective in patients with HCV genotype 2.
In this study, we analyzed 49 patients infected with HCV genotype 2 at Chiba University Hospital between January 2004 and December 2008. All patients fulfilled the following criteria: 1) a history of abnormal liver function for more than 24 weeks, 2) positivity for anti-HCV antibody and HCV RNA, 3) HCV genotype 2, 4) negativity for HBs antigen, 5) negativity for anti-HIV, 6) no high titers of anti-nuclear antibodies, 7) no history of alcohol abuse, 8) not taking immunosuppressive drugs, and 9) liver biopsy findings compatible with chronic viral hepatitis.
Patients received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. The possible risks and benefits of shorter or longer treatment with PEG-IFN were explained to the patients so as to decide on a shorter (equal to or less than 24 weeks) or longer (more than 24 weeks) treatment protocol. This study was approved by the ethics committee of Chiba University, Japan (permission number G19033), and conformed to the Helsinki Declaration. Informed consent was obtained from all patients before enrollment in this study.
Determination of HCV RNA titer and HCV genotype
Serum HCV RNA titer was measured using an Amplicor HCV monitor assay, version 2.0 (range: 0.5-850 KIU/mL) (Roche, Tokyo, Japan) . HCV RNA was also examined qualitatively with the Amplicor HCV assay (Roche). The detection limit of this qualitative assay is 50 IU/mL, corresponding to 1.7 Log IU/mL by COBAS TaqMan PCR assay . HCV genotype was determined using the antibody serotyping method of Tsukiyama-Kohara et al. [16, 17]. In this serotyping assay, HCV serotypes 1 and 2 correspond to genotypes 1a/1b and 2a/2b, respectively, according to the classification of Simmonds et al. . It was reported that in 84% patients, genotypes determined by this serological genotyping assay showed complete agreement with those determined by group-specific PCR, with none revealing a group opposite to that of the HCV genotype, and also that the detection rate of the serological genotyping assay was even higher than that of the PCR assay . HCV RNA titer and HCV genotype were determined within 3 months prior to starting IFN treatment, and HCV RNA was assayed qualitatively at 24 weeks after the end of treatment.
Serum liver function tests and hematology tests
Serum aminotransferase concentrations, other liver function tests and hematology tests were performed according to standard methods every 1 to 3 months before treatment, during treatment, and for at least 24 weeks after the end of treatment.
Liver biopsies were performed within 6 months prior to the start of treatment in cases whose informed consent was obtained. Staging of fibrosis and grading of activity were based on the classification of Desmet et al. .
Assessment of efficacy
The endpoint of the study was achievement of SVR, defined as seronegativity of HCV RNA throughout 24 weeks of post-treatment follow-up. RVR was defined as seronegativity of HCV RNA at 4 weeks of therapy. Patients who had undetectable HCV RNA within the initial 12 weeks of treatment were considered to have had complete early virological response (cEVR). End-of-treatment virological response (EOTVR) was defined as seronegativity of HCV RNA at the end of treatment. Relapse was defined as HCV RNA reappearance during the follow-up period in patients who had achieved an EOTVR .
Statistical analysis was carried out using Student's t-test or chi-square test, and p < 0.05 was considered statistically significant.
Profile of the patients
Demographic data of patients according to HCV RNA levels
Low Viral Load
High Viral Load
50.8 ± 14.5
53.3 ± 11.7
71.5 ± 56.5
100 ± 76.3
Platelets (× 104/mm3)
17.4 ± 5.5
100 ± 76.3
HCV RNA (KIU/mL)
37.5 ± 26.3
459 ± 330
Duration of treatment (days)
120 ± 80
236 ± 115
Treatment response in HCV genotype 2-patients with low viral load
Treatment response in HCV genotype 2-patients with high viral load
Treatment response in HCV genotype 2-patients with high viral load and RVR
Of the 19 patients with high viral load and RVR, SVR rates were 7/10 (70%) and 9/9 (100%) in patients treated for ≤24 weeks and > 24 weeks, respectively (P = 0.073). Of the 19 patients, 17 were treatment-naïve. The other 2 patients had been treated with IFN monotherapy, and one of them achieved SVR.
Treatment response in HCV genotype 2-patients with high viral load without RVR
The present study showed that Japanese patients with HCV genotype 2 and undetectable HCV-RNA at week 4 of treatment achieved a high SVR rate with PEG-IFN monotherapy for 24 weeks or less. In Japan, between December 2003 and March 2007, until the national health insurance system approved the combination therapy PEG-IFN-alfa-2a with RBV, PEG-IFN-alfa-2a monotherapy was used at 180 μg once a week for 24-48 weeks for the treatment of chronic hepatitis C. Even now, we cannot use the combination therapy for HCV genotype 2 treatment-naïve patients with low viral loads under the national health insurance system in our country. Then, we used 180 μg of PEG-IFN-alfa-2a monotherapies for chronic hepatitis C patients and retrospectively analyzed the data during this period in the present study. This study was not a controlled trial, and various durations of treatment were adopted for the respective patients. However, the SVR rate of 100% in patients with low viral load and 17.1 weeks as average treatment duration and that of 84.2% in those with high viral load and undetectable HCV-RNA at week 4 of average treatment duration of 24 weeks were very high. Therefore, 24 weeks of PEG-IFN therapy could represent a sufficient treatment duration for selected patients with HCV genotype 2 and undetectable HCV-RNA at week 4 of treatment.
Since IFN treatment, including PEG-IFN, can cause medical conditions such as depression, interstitial pneumonia, diabetes mellitus, thyroid disease, leukopenia, thrombocytopenia and flu-like symptoms, its duration should preferably be minimal . Therefore, to minimize the possibility of such side effects, and additionally, in consideration of the cost of IFN treatment, reducing the length of treatment is desirable [22, 23]. The combination therapy with PEG-IFN and RBV for 24 weeks has been shown to be more effective, and it has become the present standard care . However, in some cases, and especially in older patients, RBV cannot be administered because of possible side effects, including severe anemia. As patients tend to be older in Japan than in Western countries, more therapeutic options are needed.
Recently, there have been several reports about the importance of interleukin-28B (IL28B) SNP in the prediction of SVR in HCV genotype 2-patients treated with PEG-IFN-alfa plus RBV therapy [20, 24–28]. IL28B SNP rs8099917 was determined in 11 HCV genotype 2-patients treated with IFN monotherapy, revealing that 5 and 6, respectively, had major (TT) and minor (TG and GG) phenotypes and that 2 null-responders had TG phenotypes, and 4 had relapsed and 5 had SVR [, data not shown]. It is possible that IL28B SNP could improve the SVR rate in non-RVR patients and non-responder patients by changing monotherapy to combination therapy , but further studies will be needed.
Recently, there have been reports that in HCV genotype 2/3-infected patients with a very rapid viral response (vRVR), i.e. HCV RNA below 1,000 IU/mL on day 7, the combination PEG-IFN plus RBV treatment could be shortened to 12-16 weeks if no dose reduction had been made . Further studies will be needed to reveal how long patients obtaining RVR should be treated. Our study indicates that PEG-IFN monotherapy for 24 weeks or less is sufficient to treat patients with HCV genotype 2, especially those who become negative for HCV RNA by week 4 of treatment. On the other hand, RBV combination therapy should be considered in those whose HCV RNA becomes seropositive by week 4 of treatment. Our results need to be confirmed by a randomized control study as soon as possible. Our previous studies showed that the overall SVR rate of HCV genotype 2-patients treated with PEG-IFN-alfa-2b plus RBV for 16-48 weeks was 82.6% , and the SVR rate of combination treatments for some patients infected with HCV genotype 2 was superior to that of PEG-IFN-alfa-2a monotherapy (75.5%) in the present study. Although our retrospective study had a rather small sample size with various treatment durations, our results may provide support to the future design of personalized therapy for HCV genotype 2-patients in certain situations where they cannot be treated with RBV.
PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment. If we could use IL28B SNP and vRVR for selecting patients, PEG-IFN-alfa-2a monotherapy would be sufficient to allow some HCV genotype 2-patients to clear HCV.
This study was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
- Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Hepatology. 1997, 3 (Suppl 1): 34S-38S.View ArticleGoogle Scholar
- Ahmed A, Keeffe EB: Hepatitis C virus and liver transplantation. Clin Liver Dis. 2001, 5: 1073-1090. 10.1016/S1089-3261(05)70210-5.PubMedView ArticleGoogle Scholar
- Kanda T, Imazeki F, Yokosuka O: New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010, 4: 548-561. 10.1007/s12072-010-9193-3.PubMedPubMed CentralView ArticleGoogle Scholar
- Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS: Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009, 136: 496-504. 10.1053/j.gastro.2008.10.049.PubMedView ArticleGoogle Scholar
- Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S, ACCELERATE Investigators: Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007, 357: 124-134. 10.1056/NEJMoa066403.PubMedView ArticleGoogle Scholar
- Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005, 352: 2609-2617. 10.1056/NEJMoa042608.PubMedView ArticleGoogle Scholar
- Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, Dhillon AP, Also A, Hellstrand K, Westin J, Norkrans G: Randomized comparison of 12 or 24 weeks of peginterferon aipha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008, 47: 1837-1845. 10.1002/hep.22253.PubMedView ArticleGoogle Scholar
- Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, Merli M, Strazzabosco M, Tisone G: A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007, 46: 1009-1017.PubMedView ArticleGoogle Scholar
- Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Kao JH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS: Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomized study. Gut. 2008, 57: 525-530.PubMedView ArticleGoogle Scholar
- Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000, 343: 1673-1680. 10.1056/NEJM200012073432302.PubMedView ArticleGoogle Scholar
- Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000, 343: 1666-1672. 10.1056/NEJM200012073432301.PubMedView ArticleGoogle Scholar
- McHutchison JG, Poynard T: Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 1999, 19 (suppl 1): 57-65.PubMedGoogle Scholar
- Yokosuka O, Iwama S, Suzuki N, Takashi M, Hirai Y, Uchiumi K, Kimura M, Gotou N, Hino S, Hayasaka A, Kanda T, Kawai S, Fukai K, Imazeki F, Saisho H: High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study. Intervirology. 2004, 47: 328-334. 10.1159/000080876.PubMedView ArticleGoogle Scholar
- Young KKY, Resnick RM, Myers TW: Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 1993, 31: 882-886.PubMedPubMed CentralGoogle Scholar
- Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Sugiura N, Tawada A, Wu S, Tanaka M, Nakamoto S, Mikata R, Tada M, Chiba T, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O: Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat. 2011, 18: e292-e297. 10.1111/j.1365-2893.2010.01409.x.PubMedView ArticleGoogle Scholar
- Tsukiyama-Kohara K, Yamaguchi K, Maki N, Ohta Y, Miki K, Mizokami M, Ohba K, Tanaka S, Hattori N, Nomoto A, Kohara M: Antigenicities of group I and II hepatitis virus polypeptides-molecular basis of diagnosis. Virology. 1993, 192: 430-437. 10.1006/viro.1993.1058.PubMedView ArticleGoogle Scholar
- Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta Y, Hattori N, Kohara M: Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology. 1994, 19: 1347-1353. 10.1002/hep.1840190605.PubMedView ArticleGoogle Scholar
- Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC: Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol. 1993, 74: 661-668. 10.1099/0022-1317-74-4-661.PubMedView ArticleGoogle Scholar
- Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994, 19: 1513-1520. 10.1002/hep.1840190629.PubMedView ArticleGoogle Scholar
- Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL: Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology. 2011, 53: 7-13. 10.1002/hep.23976.PubMedView ArticleGoogle Scholar
- Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-Analysis of Interferon Randomized Trials in the treatment of Viral Hepatitis C: Effects of Dose and Duration. Hepatology. 1996, 24: 778-789. 10.1002/hep.510240405.PubMedView ArticleGoogle Scholar
- Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995, 22: 1050-1056.PubMedView ArticleGoogle Scholar
- Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993, 341: 1501-1504. 10.1016/0140-6736(93)90635-T.PubMedView ArticleGoogle Scholar
- Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG: An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010, 139: 821-827. 10.1053/j.gastro.2010.05.079.PubMedView ArticleGoogle Scholar
- Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T: Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011, 54: 415-421. 10.1016/j.jhep.2010.07.041.PubMedView ArticleGoogle Scholar
- Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Tsunoda T, Nakamura Y, Kumada H, Chayama K: Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol. 2011, 54: 408-414. 10.1016/j.jhep.2010.07.032.PubMedView ArticleGoogle Scholar
- Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M, Ochanomizu-Liver Conference Study Group: Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol. 2011, 83: 871-878. 10.1002/jmv.22038.PubMedView ArticleGoogle Scholar
- Lindh M, Lagging M, Farkkila M, Langeland N, Morch K, Nilsson S, Norkrans G, Pedersen C, Buhl MR, Westin J, Hellstrand K: Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis. 2011, 203: 1748-1752. 10.1093/infdis/jir193.PubMedView ArticleGoogle Scholar
- Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, Fujiwara K, Yokosuka O: Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol. 2011, 46: 955-961. 10.3109/00365521.2011.574731.PubMedView ArticleGoogle Scholar
- Kanda T, Imazeki F, Azemoto R, Yonemitsu Y, Mikami S, Kita K, Takashi M, Sunaga M, Wu S, Nakamoto S, Tawada A, Arai M, Kato K, Yoshida Y, Koma Y, Fujiwara K, Fukai K, Suzuki N, Yokosuka O: Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci. 2011,Google Scholar
- Lagging M, Wejstal R, Uhnoo I, Gerden B, Fischler B, Friman S, Josephson F, Karlstrom O, Sangfelt P, Schvarz R, Weiland O, Swedish Consensus Group: Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis. 2009, 41: 389-402. 10.1080/00365540902998271.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.